Globe Newswire (Mon, 20-Apr 9:00 AM ET)
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Globe Newswire (Mon, 13-Apr 8:30 AM ET)
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Globe Newswire (Wed, 25-Mar 6:30 PM ET)
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Globe Newswire (Tue, 17-Mar 8:30 AM ET)
Oragenics Targets Brain Health Expansion with CNS Acquisition Plans Amid Progress in ONP-002 Trials
Market Chameleon (Thu, 12-Mar 7:45 AM ET)
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Globe Newswire (Thu, 12-Mar 8:30 AM ET)
Globe Newswire (Wed, 11-Mar 8:30 AM ET)
Globe Newswire (Tue, 10-Mar 8:30 AM ET)
Globe Newswire (Mon, 9-Feb 8:30 AM ET)
Globe Newswire (Tue, 3-Feb 8:30 AM ET)
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Oragenics trades on the AMEX stock market under the symbol OGEN.
As of April 22, 2026, OGEN stock price climbed to $0.67 with 13,708 million shares trading.
OGEN has a beta of 2.16, meaning it tends to be more sensitive to market movements. OGEN has a correlation of 0.05 to the broad based SPY ETF.
OGEN has a market cap of $2.91 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, OGEN traded as high as $232.20 and as low as $.50.
OGEN has underperformed the market in the last year with a return of -87.8%, while the SPY ETF gained +39.5%. In the last 3 month period, OGEN fell short of the market, returning -32.3%, while SPY returned +3.8%. However, in the most recent 2 weeks OGEN has outperformed the stock market by returning +18.2%, while SPY returned +7.6%.
OGEN support price is $.61 and resistance is $.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGEN shares will trade within this expected range on the day.